Company intelligence / Profile preview

Silver Creek CS

San Francisco, California, United Statessilvercreekpharma.com ↗

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Silver Creek Pharmaceuticals is a clinical-stage biotech company developing targeted recombinant fusion proteins, primarily focusing on rescuing damaged tissues. Its lead asset, scp776, a first-in-class IGF-1R-targeted fusion protein, has demonstrated preclinical efficacy in models of stroke, heart attack, and kidney injury, and is currently in a Phase II study for acute ischemic stroke[1].

Therapeutic areas: NephrologyCardiovascular
Modalities: Recombinant fusion proteinTargeted protein therapeutic
Industry: Biotech

Drug pipeline

1 asset

scp776

Phase 2

Indications: Acute ischemic stroke, Heart attack, Kidney injury

Beyond the preview

Go deeper on Silver Creek CS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Silver Creek CS.

Explore the full profile